Search - tctmd.com

Displaying 101 - 120 of 130

Sort: Relevancy | Date

News Daily News

Surviving CVD: Obesity Offers No Protection for Those With New Onset Cardiac Events

Michael O'Riordan

December 07, 2017

News Daily News

Diabetes Remission Possible With Significant Weight Loss: DiRECT

Michael O'Riordan

December 05, 2017

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Daily News

Statins and Diabetes: Causal Link Reinforced in New Analysis

Michael O'Riordan

October 25, 2017

News Daily News

Higher BMI Linked to Increased Risk of CHD, Hypertension, and Diabetes

Michael O'Riordan

July 06, 2017

News Daily News

Optimal Cardiovascular Health Not Offset by Poor Health as a Whole

Ashley Lyles

June 20, 2017

News Daily News

‘Sizeable’ Segment of Public, Even When at High CVD Risk, Feels No Need to Improve Health

Michael O'Riordan

May 04, 2017

Presentation EAS 2017

Diet and Cardiometabolic Health

Presenter: Qi Sun

May 03, 2017

News Daily News

Trans Fat Ban Led to Tangible CVD Benefits, New York State Analysis Shows

Michael O'Riordan

April 12, 2017

News Daily News

A Deadly Diet: Half of US Deaths From Cardiometabolic Causes Linked to Dietary Habits

Michael O'Riordan

March 08, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Shelley Wood

December 02, 2016

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

News Daily News

Las Variantes del Gen PCSK9 se asocian a Niveles Más Bajos de Colesterol LBD y a un Mayor Riesgo de Diabetes

Michael O'Riordan

December 01, 2016

News Daily News

Pokémon Go Forth: Cardiologists, AHA Support Use of Augmented Reality Games That Encourage Movement

Yael L. Maxwell

July 22, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Deadly Deceleration? Annual Declines in US Cardiovascular Death Rate Start to Slow

Caitlin E. Cox

June 30, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Industry News

U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)

January 24, 2016

News Daily News

Refreshed Dietary Guidelines Shift Focus to Healthy Eating Patterns

Todd Neale

January 18, 2016

Advertisement

Surviving CVD: Obesity Offers No Protection for Those With New Onset Cardiac Events

Diabetes Remission Possible With Significant Weight Loss: DiRECT

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Statins and Diabetes: Causal Link Reinforced in New Analysis

Higher BMI Linked to Increased Risk of CHD, Hypertension, and Diabetes

Optimal Cardiovascular Health Not Offset by Poor Health as a Whole

‘Sizeable’ Segment of Public, Even When at High CVD Risk, Feels No Need to Improve Health

Diet and Cardiometabolic Health

Trans Fat Ban Led to Tangible CVD Benefits, New York State Analysis Shows

A Deadly Diet: Half of US Deaths From Cardiometabolic Causes Linked to Dietary Habits

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Las Variantes del Gen PCSK9 se asocian a Niveles Más Bajos de Colesterol LBD y a un Mayor Riesgo de Diabetes

Pokémon Go Forth: Cardiologists, AHA Support Use of Augmented Reality Games That Encourage Movement

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Deadly Deceleration? Annual Declines in US Cardiovascular Death Rate Start to Slow

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)

Refreshed Dietary Guidelines Shift Focus to Healthy Eating Patterns

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content